

# Hermine I Brunner

## List of Publications by Citations

Source: <https://exaly.com/author-pdf/2144796/hermine-i-brunner-publications-by-citations.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194  
papers

8,160  
citations

45  
h-index

85  
g-index

205  
ext. papers

9,807  
ext. citations

6.1  
avg, IF

5.67  
L-index

#	Paper	IF	Citations
194	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2385-95	59.2	577
193	Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2396-406	59.2	484
192	Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 556-62		354
191	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 891-7	4.7	268
190	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 481-9	2.4	247
189	Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 436-44		235
188	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 566-76	9.5	216
187	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2012-21		202
186	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1110-7	2.4	195
185	Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2577-84		185
184	Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. <i>Rheumatic Disease Clinics of North America</i> , <b>2010</b> , 36, 53-80, vii-viii	2.4	176
183	International consensus on preliminary definitions of improvement in adult and juvenile myositis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 2281-90		173
182	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , <b>2017</b> , 8, 16021	17.4	171
181	Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1354-60		154
180	Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 375-83	4.7	131
179	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2607-15		121
178	Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2687-97		113

177	Taxonomy for systemic lupus erythematosus with onset before adulthood. <i>Arthritis Care and Research</i> , 2012, 64, 1787-93	4.7	109
176	Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. <i>Arthritis and Rheumatism</i> , 2009, 60, 1496-507		109
175	Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. <i>Arthritis and Rheumatism</i> , 2009, 60, 2772-81		108
174	Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. <i>Pediatric Nephrology</i> , 2008, 23, 403-12	3.2	104
173	Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. <i>Pediatric Research</i> , 2009, 65, 530-6	3.2	94
172	Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 174-9	4.1	88
171	Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, 218	5.7	81
170	Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. <i>Arthritis and Rheumatism</i> , 2004, 51, 763-73		81
169	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 218-28	9.5	81
168	Preliminary definition of disease flare in juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1058-64	4.1	81
167	Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. <i>Arthritis and Rheumatism</i> , 2007, 57, 1000-6		75
166	Adherence to medications in systemic lupus erythematosus. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 195-201	1.1	73
165	Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. <i>Arthritis and Rheumatism</i> , 1999, 42, 2346-55		69
164	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 21-29	2.4	64
163	Disease control and health-related quality of life in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 393-9		62
162	Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. <i>Arthritis and Rheumatology</i> , 2019, 71, 1943-1954	9.5	61
161	Identification of a urinary proteomic signature for lupus nephritis in children. <i>Pediatric Nephrology</i> , 2007, 22, 2047-57	3.2	59
160	Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. <i>Arthritis and Rheumatism</i> , 2007, 56, 4151-63		57

159	Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 557-66 <sup>24</sup>	54
158	Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 1174-82	54
157	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1710-1719	2.4 53
156	Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 840-8	9.5 52
155	Pain, Fatigue, and Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 73-80	4.7 49
154	Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1163-70	4.1 48
153	Health-related quality of life in children with rheumatic diseases. <i>Current Opinion in Rheumatology</i> , <b>2003</b> , 15, 602-12	5.3 48
152	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1340-1348 <sup>24</sup>	48
151	Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1536-45	4.1 47
150	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , <b>2016</b> , 2, e000161	5.9 46
149	Pediatric SLE--towards a comprehensive management plan. <i>Nature Reviews Rheumatology</i> , <b>2011</b> , 7, 225-33 <sup>31</sup>	45
148	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 40, 307-13	5.3 45
147	European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, 335-41	45
146	International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 1416-23	4.7 44
145	Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3131-9	43
144	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1003-11	4.7 42
143	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 86	3.5 41
142	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 1-24	6.2 41

141	Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. <i>Journal of Pediatrics</i> , <b>2018</b> , 196, 22-30.e2	3.6	39
140	Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R199	5.7	39
139	Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. <i>Journal of Clinical Rheumatology</i> , <b>2005</b> , 11, 194-204	1.1	39
138	Minimal clinically important differences of the childhood health assessment questionnaire. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 150-61	4.1	39
137	Differences in disease outcomes between medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 378-84		38
136	Determinants of health-related quality of life in children newly diagnosed with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 263-9	4.7	36
135	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 13	5.7	35
134	Developing outcome measures for paediatric rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 609-24	5.3	35
133	Specialized Neuromuscular Training to Improve Neuromuscular Function and Biomechanics in a Patient With Quiescent Juvenile Rheumatoid Arthritis. <i>Physical Therapy</i> , <b>2005</b> , 85, 791-802	3.3	35
132	Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1144-1154	9.5	33
131	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 727-40	3.8	32
130	Urine S100 proteins as potential biomarkers of lupus nephritis activity. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 242	5.7	31
129	Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology. <i>Pediatric Rheumatology</i> , <b>2018</b> , 16, 45	3.5	30
128	Environmental triggers in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 710-717	5.3	29
127	Inactive disease and remission in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 683-93	4.7	29
126	Cost of treatment of childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 184-8		29
125	Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1377-85	9.5	28
124	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2419-26	4.1	28

123	Biomarkers and updates on pediatrics lupus nephritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2013</b> , 39, 833-53	2.4	28
122	Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 950-9	4.7	28
121	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , <b>2017</b> , 184, 38-44.e1	6.1	26
120	Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2459-65	4.1	26
119	Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 372-81	4.7	26
118	Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1239-1248	4.1	25
117	Advances in the care of children with lupus nephritis. <i>Pediatric Research</i> , <b>2017</b> , 81, 406-414	3.2	25
116	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1213-23	4.7	25
115	A proposed framework to standardize the neurocognitive assessment of patients with pediatric systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 1029-33	4.7	24
114	Validation of Patient-Reported Outcomes Measurement Information System Short Forms for Use in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 133-142	4.7	23
113	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 451-459	9.5	23
112	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 2392-2404	5.6	22
111	Academic outcomes in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1167-74	4.7	22
110	Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. <i>Pediatric Nephrology</i> , <b>2019</b> , 34, 117-128	3.2	22
109	Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 490-501	4.1	22
108	Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. <i>Pediatric Rheumatology</i> , <b>2014</b> , 12, 29	3.5	21
107	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 401-6	2.4	21
106	Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 811-20	4.7	21

105	Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 179-86	4.7	19
104	Functional neuronal network activity differs with cognitive dysfunction in childhood-onset systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, R40	5.7	18
103	Brain morphometric changes associated with childhood-onset systemic lupus erythematosus and neurocognitive deficit. <i>Arthritis and Rheumatism</i> , 2013, 65, 2190-200		18
102	Pain, Fatigue, Family Functioning, and Attitude Toward Illness in Children with Juvenile Rheumatic Diseases. <i>Journal of Developmental and Physical Disabilities</i> , 2007, 19, 135-144	1.5	18
101	Current medication choices in juvenile rheumatoid arthritis II--update of a survey performed in 1993. <i>Journal of Clinical Rheumatology</i> , 2001, 7, 295-300	1.1	18
100	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013	4.1	18
99	Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 195-202	4.7	17
98	Altered Blood-Brain Barrier Permeability in Patients With Systemic Lupus Erythematosus: A Novel Imaging Approach. <i>Arthritis Care and Research</i> , 2017, 69, 299-305	4.7	17
97	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518	9.5	17
96	Biomarkers for childhood-onset systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2015, 17, 471	4.9	16
95	American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 813-822	4.7	16
94	Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1621-1629	4.7	16
93	Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study. <i>Journal of Rheumatology</i> , 2011, 38, 1020-5	4.1	16
92	Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1119-27	4.7	15
91	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1945-1951	9.5	15
90	The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. <i>Pediatric Rheumatology</i> , 2020, 18, 7	3.5	15
89	Biomarkers for renal disease in childhood. <i>Current Rheumatology Reports</i> , 2009, 11, 218-25	4.9	15
88	Item weightings for the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index using Rasch analysis do not lead to an important improvement. <i>Journal of Rheumatology</i> , 2003, 30, 292-7	4.1	15

87	Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 335-44	4.7	14
86	Relationship of cell-free urine MicroRNA with lupus nephritis in children. <i>Pediatric Rheumatology</i> , <b>2016</b> , 14, 4	3.5	13
85	Tocilizumab for treating juvenile idiopathic arthritis. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 559-66	13	
84	Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus. <i>Journal of Pediatrics</i> , <b>2006</b> , 148, 571-3	3.6	13
83	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. <i>Lancet, The</i> , <b>2021</b> , 398, 1984-1996	40	13
82	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 2147-2158	9.5	13
81	Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. <i>Pediatric Rheumatology</i> , <b>2018</b> , 16, 65	3.5	13
80	Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1743-1750	4.7	12
79	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 579-590	4.7	12
78	Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. <i>Cell Reports Medicine</i> , <b>2020</b> , 1,	18	12
77	Effects of age and gender on reference levels of biomarkers comprising the pediatric Renal Activity Index for Lupus Nephritis (p-RAIL). <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 74	3.5	12
76	Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , <b>2016</b> , 14, 11	3.5	12
75	Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000038	4.6	12
74	Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 658-62	3.2	12
73	Update on the treatment and outcome of systemic lupus erythematosus in children. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 464-470	5.3	12
72	Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity. <i>Rheumatology</i> , <b>2019</b> , 58, 321-330	3.9	12
71	Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 251-259	5.3	11
70	Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 51, 899-908	11	

69	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1420-1430	4.7	11
68	Proteomic profiling of urine: implications for lupus nephritis. <i>Expert Review of Proteomics</i> , <b>2019</b> , 16, 303-313	4.1	10
67	Value of questionnaire-based screening as a proxy for neurocognitive testing in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 943-8	4.7	10
66	Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 1524-36	3.5	10
65	Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1449-1459	4.7	9
64	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1117-1126	4.1	9
63	Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment. <i>Pediatric Rheumatology</i> , <b>2019</b> , 17, 9	3.5	9
62	Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 580-585	4.7	9
61	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. <i>Pediatric Rheumatology</i> , <b>2020</b> , 18, 19	3.5	8
60	Extrapolation or controlled trials in paediatrics: the current dilemma. <i>Archives of Disease in Childhood</i> , <b>2017</b> , 102, 949-951	2.2	8
59	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1884-1888	4.1	8
58	The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 212-7	4.9	8
57	Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	8
56	Elevated serum complement levels and higher gene copy number of complement are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE). <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000333	4.6	8
55	Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 530-541	9.5	8
54	Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. <i>Pediatric Rheumatology</i> , <b>2020</b> , 18, 43	3.5	7
53	Malignancy in Pediatric-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1484-1486	4.6	7
52	Juvenile idiopathic arthritis.. <i>Nature Reviews Disease Primers</i> , <b>2022</b> , 8, 5	51.1	7

51	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
50	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 336-346	9.5	7
49	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1898-1909	9.5	7
48	Brain gray matter volume differences in obese youth with type 2 diabetes: a pilot study. <i>Journal of Pediatric Endocrinology and Metabolism</i> , <b>2018</b> , 31, 261-268	1.6	6
47	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S8-S9	9.5	6
46	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1636-1644	4.7	6
45	Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1506-1513	4.1	6
44	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1173-1179	4.1	6
43	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 107-125	6.2	5
42	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , <b>2018</b> , 38, 35-42	3.6	5
41	School Support and Functioning for Children with Juvenile Rheumatic Diseases. <i>Journal of Developmental and Physical Disabilities</i> , <b>2007</b> , 19, 81-89	1.5	5
40	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	5
39	Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	5
38	Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 162-170	3.4	5
37	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 4568-4580	3.9	5
36	Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkinIndex27 for use in childhood-onset systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000275	4.6	5
35	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S5-S6	9.5	4
34	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 852-858	4.1	4

33	Pharmacokinetic modeling of therapies for systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 587-603	3.8	3
32	Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	3
31	Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 135	5.7	3
30	Rash, Fever, and Pulmonary Hypertension in a 6-Year-Old Female. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 785-790	4.7	3
29	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S86-S87	9.5	3
28	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S23-S24	9.5	3
27	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 605060	5.6	3
26	Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , <b>2020</b> , 22, 653-672	4.2	3
25	International Consensus For The Dosing Of Corticosteroids In Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	3
24	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 4495-4507	3.9	3
23	TRIAL DESIGN, MEASUREMENT, AND ANALYSIS OF CLINICAL INVESTIGATIONS <b>2011</b> , 127-156		2
22	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 211	5.7	2
21	Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity. <i>Kidney International Reports</i> , <b>2021</b> , 6, 1949-1960	4.1	2
20	Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et Al. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 857-8	9.5	1
19	Polyarticular Arthritis and Skin Nodulosis in a 14-Year-Old Female. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 700-5	4.7	1
18	Trial Design, Measurement, and Analysis of Clinical Investigations <b>2016</b> , 54-77.e2		1
17	A52: The Impact of Adalimumab on Growth in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S77-S78	9.5	1
16	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S96-S97	9.5	1

15	A22: Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis—Status of Use in Daily Clinical Care. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S35-S36	9.5	1
14	Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. <i>Cytotherapy</i> , <b>2021</b> , 23, 37-45	4.8	1
13	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
12	Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2022</b> , 48, 271-285	2.4	0
11	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1264-1274	4.7	0
10	Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis.. <i>Lupus</i> , <b>2021</b> , 9612033261062515		
9	A33: Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S51-S52	9.5	
8	A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, S222-S223	9.5	
7	SLE in Children <b>2011</b> , 573-597		
6	Neuroinflammation and Pediatric Lupus <b>2011</b> , 423-437		
5	Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1379-1386	4.7	
4	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1073-1081	4.1	
3	Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus <b>2021</b> , 159-180		
2	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 842586	4.9	
1	Tofacitinib for juvenile idiopathic arthritis - AuthorsSreply.. <i>Lancet, The</i> , <b>2022</b> , 399, 1866	4.0	